Garcia Marino: insider trades.
Garcia Marino reported 9 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($17.9M), across 1 company.
- Transactions
- 9
- Purchases (P)
- 0
- Sales (S)
- 7
- Companies
- 1
- Name as filed
- Garcia Marino
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | Director, Officer · CEO AND PRESIDENT | 9 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 2,373 | $109.1 | 194,628 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 2,536 | $110.02 | 192,092 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 800 | $110.76 | 191,292 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 104,091 | $107.96 | 87,102 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 23,907 | $108.05 | 197,001 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | M | 40,000 | $8.44 | 105,292 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | M | 126,000 | $8.44 | 231,292 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 10,384 | $107.49 | 220,908 | Form 4 |
| 2026-08-07 | Dianthus Therapeutics, Inc. /DE/ | S | 21,909 | $108.72 | 65,292 | Form 4 |
Questions
What stock did Garcia Marino buy or sell?
Garcia Marino reported 9 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 7 sales ($17.9M), across 1 company.
Is Garcia Marino the same person as other filers with this name?
This page covers SEC CIK 1669866 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/garcia-marino-1669866.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.